Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis

被引:58
作者
Coss, Alan [1 ]
Tose, Miriam [2 ]
Fox, Edward J. [2 ]
Sapetto-Rebow, Beata [3 ]
Gorman, Sheeona [1 ]
Kennedy, Breanddn N. [3 ]
Lloyd, Andrew T. [4 ]
Hyland, John M. [1 ]
O'Donoghue, Diarmuid P. [1 ]
Sheahan, Kieran [1 ]
Leahy, Dermot T. [2 ]
Mulcahy, Hugh E. [1 ]
O'Sullivan, Jacintha N. [1 ]
机构
[1] St Vincents Univ Hosp, Ctr Colorectal Dis, Dublin 4, Ireland
[2] Univ Coll Dublin, Conway Inst, Sch Med & Med Sci, Dublin, Ireland
[3] Univ Coll Dublin, Conway Inst, Sch Biomol & Biomed Sci, Dublin, Ireland
[4] Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland
关键词
Topisomerase II; Colorectal cancer; Oncology; Drug resistance; HER2; Colon cancer; Chemotherapy; Gene amplification; Cell cycle; Disease progression; Array CGH; COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; PRIMARY BREAST-CANCER; GENE AMPLIFICATION; CELL-LINES; PREDICTIVE MARKERS; PROTEIN EXPRESSION; C-ERBB-2; PROTEIN; DRUG-RESISTANCE; COLON-CANCER;
D O I
10.1016/j.canlet.2008.11.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Topoisomerase II alpha is a nuclear enzyme that regulates the tertiary structure of DNA. The influence of topoisomerase II alpha gene (TOP2A) or protein alterations on disease progression and treatment response in colorectal cancer (CRC) is unknown. The study investigated the clinical relevance of topoisomerase II alpha in CRC using in vivo and in vitro models. Differentially expressed genes in early and late-stage CRC were identified by array comparative genomic hybridization (CGH). Cellular location of gene amplifications was determined by fluorescence in situ hybridization (FISH). Topoisomerase II alpha levels, proliferation index, and HER2 expression were examined in 228 colorectal tumors by immunohistochemistry. Overexpression of topoisomerase II alpha in vitro was achieved by liposome-based transfection. Cell growth inhibition and apoptosis were quantified using the crystal violet assay and flow cytometry, respectively, in response to drug treatment. Amplification of TOP2A was identified in 3 (7.7%) tumors using array CGH and confirmed using FISH. At the protein level, topoisomerase II alpha staining was observed in 157 (69%) tumors, and both staining and intensity levels were associated with an aggressive tumor phenotype (p values 0.04 and 0.005, respectively). Using logistic regression analysis, topoisomerase II alpha remained significantly associated with advanced tumor stage when corrected for tumor proliferation (p = 0.007) and differentiation (p = 0.001). No association was identified between topoisomerase II alpha and HER2. In vitro, overexpression of topoisomerase II alpha was associated with resistance to irinotecan (p = 0.001) and etoposide chemotherapy (p = 0.03), an effect mediated by inhibition of apoptosis. Topoisomerase II alpha overexpression is significantly associated with alterations in tumor behavior and response to drug treatment in CRC. Our results suggest that gene amplification may represent an important mechanism underlying these changes. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:228 / 238
页数:11
相关论文
共 43 条
[1]   HER2, TOP2A, CCND1, EGFR and c-MYC oncogene amplification in colorectal cancer [J].
Al-Kuraya, Khawla ;
Novotny, Hedvika ;
Bavi, Prashant ;
Siraj, Abdul K. ;
Uddin, Shahab ;
Ezzat, Adnan ;
Al Sanea, Nasser ;
Al-Dayel, Fouad ;
Al-Mana, Hadeel ;
Sheikh, Salwa S. ;
Mirlacher, Martina ;
Tapia, Coya ;
Simon, Ronald ;
Sauter, Guido ;
Terracciano, Luigi ;
Tornillo, Luigi .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) :768-772
[2]  
[Anonymous], CANC STAG MAN
[3]   HER2 (C-ERBB-2) ONCOPROTEIN EXPRESSION IN COLORECTAL ADENOCARCINOMA - AN IMMUNOHISTOLOGICAL STUDY USING 3 DIFFERENT ANTIBODIES [J].
ARNAOUT, AH ;
DAWSON, PM ;
SOOMRO, S ;
TAYLOR, P ;
THEODOROU, NA ;
FELDMANN, M ;
FENDLY, BM ;
SHEPARD, HM ;
SHOUSHA, S .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (08) :726-727
[4]  
Bartlett J M., 2008, J Clin Oncol
[5]   TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas [J].
Bofin, AM ;
Ytterhus, B ;
Hagmar, BM .
CYTOPATHOLOGY, 2003, 14 (06) :314-319
[6]   Genome-wide differences between microsatellite stable and unstable colorectal tumors [J].
Camps, J ;
Armengol, G ;
del Rey, J ;
Lozano, JJ ;
Vauhkonen, H ;
Prat, E ;
Egozcue, J ;
Sumoy, L ;
Knuutila, S ;
Miró, R .
CARCINOGENESIS, 2006, 27 (03) :419-428
[7]   Between-group analysis of microarray data [J].
Culhane, AC ;
Perrière, G ;
Considine, EC ;
Cotter, TG ;
Higgins, DG .
BIOINFORMATICS, 2002, 18 (12) :1600-1608
[8]   Deletion at chromosome band 20p 12.1 in colorectal cancer revealed by high resolution array comparative genomic hybridization [J].
Davison, EJ ;
Tarpey, PS ;
Fiegler, H ;
Tomlinson, IPM ;
Carter, NP .
GENES CHROMOSOMES & CANCER, 2005, 44 (04) :384-391
[9]  
Di Leo A, 2002, CLIN CANCER RES, V8, P1107
[10]   Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas [J].
Douglas, EJ ;
Fiegler, H ;
Rowan, A ;
Halford, S ;
Bicknell, DC ;
Bodmer, W ;
Tomlinson, IPM ;
Carter, NP .
CANCER RESEARCH, 2004, 64 (14) :4817-4825